LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES

被引：0
|
作者：
Kaura, S. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Augmentium Pharma Consulting, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1727
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A508 / A509
页数：2
相关论文
共 50 条
  • [31] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
  • [32] COMPARISONS OF REGIMEN COSTS OF BORTEZOMIB AND LENALIDOMIDE FOR TREATMENT OF ADVANCED, RELAPSED MULTIPLE MYELOMA
    Hornberger, J.
    Rickert, J.
    Dhawan, R.
    Baldesano, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 477 - 477
  • [33] Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
    Siegel, David Samuel DiCapua
    McBride, Laura
    Bilotti, Elizabeth
    Schmidt, Linda
    Gao, Zhijie
    Tufail, Madiha
    Lendvai, Nikoletta
    McNeill, Ann
    Donadio, Kristen
    Olivo, Karly
    Bednarz, Urzula
    Graef, Thorsten
    Vesole, David H.
    BLOOD, 2010, 116 (21) : 1264 - 1264
  • [34] Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)
    Oster, Gerry
    Berger, Ariel
    Bornheimer, Rebecca
    Binder, Gary
    Nagarwala, Yasir
    BLOOD, 2013, 122 (21)
  • [35] Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison
    Weisel, Katja C.
    Dhanasiri, Sujith
    Gauthier, Aline
    Padhiar, Amie
    Casal, Eva
    Richardson, Paul G.
    BLOOD, 2019, 134
  • [36] Lenalidomide A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
    Scott, Lesley J.
    Lyseng-Williamson, Katherine A.
    DRUGS, 2011, 71 (05) : 625 - 649
  • [37] Patient eligibility for lenalidomide/dexamethasone treatment in relapsed/refractory multiple myeloma
    Palumbo, A.
    Dimopoulos, M.
    San Miguel, J.
    Harousseau, J. L.
    Attal, M.
    Hussein, M.
    Knop, S.
    Ludwig, H.
    Sonneveld, P.
    von Lilienfeld-Toal, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 97 - 97
  • [38] Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice
    Wu, Ka Lung
    van Wieringen, Wessel
    Vellenga, Edo
    Zweegman, Sonja
    Lokhorst, Henk M.
    Sonneveld, Pieter
    HAEMATOLOGICA, 2005, 90 (07) : 996 - 997
  • [39] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL- LIFE EXPERIENCE
    Cerchione, C.
    Zacheo, I
    Di, Perna M.
    Nappi, D.
    Pareto, A. E.
    Peluso, I
    Ferrara, K.
    Pane, F.
    Catalano, l
    HAEMATOLOGICA, 2018, 103 : 39 - 40
  • [40] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Pareto, A. E.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2017, 102 : 140 - 140
12345